BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 37237279)

  • 21. Involvement of Host ATR-CHK1 Pathway in Hepatitis B Virus Covalently Closed Circular DNA Formation.
    Luo J; Luckenbaugh L; Hu H; Yan Z; Gao L; Hu J
    mBio; 2020 Feb; 11(1):. PubMed ID: 32071277
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
    Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
    Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
    Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
    Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ATR-Chk1 signaling pathway and homologous recombinational repair protect cells from 5-fluorouracil cytotoxicity.
    Fujinaka Y; Matsuoka K; Iimori M; Tuul M; Sakasai R; Yoshinaga K; Saeki H; Morita M; Kakeji Y; Gillespie DA; Yamamoto K; Takata M; Kitao H; Maehara Y
    DNA Repair (Amst); 2012 Mar; 11(3):247-58. PubMed ID: 22188649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reconstitution of human claspin-mediated phosphorylation of Chk1 by the ATR (ataxia telangiectasia-mutated and rad3-related) checkpoint kinase.
    Lindsey-Boltz LA; Serçin O; Choi JH; Sancar A
    J Biol Chem; 2009 Nov; 284(48):33107-14. PubMed ID: 19828454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Requirement of MTA1 in ATR-mediated DNA damage checkpoint function.
    Li DQ; Ohshiro K; Khan MN; Kumar R
    J Biol Chem; 2010 Jun; 285(26):19802-12. PubMed ID: 20427275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring Chk1 kinase activity dynamics in live single cell imaging assays.
    Lebrec V; Gavet O
    Methods Cell Biol; 2024; 182():221-236. PubMed ID: 38359979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism.
    Pereira DM; Simões AE; Gomes SE; Castro RE; Carvalho T; Rodrigues CM; Borralho PM
    Oncotarget; 2016 Jun; 7(23):34322-40. PubMed ID: 27144434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Critical role of SMG7 in activation of the ATR-CHK1 axis in response to genotoxic stress.
    Ho K; Luo H; Zhu W; Tang Y
    Sci Rep; 2021 Apr; 11(1):7502. PubMed ID: 33820915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multi-Level Control of the ATM/ATR-CHK1 Axis by the Transcription Factor E4F1 in Triple-Negative Breast Cancer.
    Batnini K; Houles T; Kirsh O; Du Manoir S; Zaroual M; Delpech H; Fallet C; Lacroix M; Le Cam L; Theillet C; Sardet C; Rodier G
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012478
    [No Abstract]   [Full Text] [Related]  

  • 31. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
    Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
    Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.
    Demidova AR; Aau MY; Zhuang L; Yu Q
    J Biol Chem; 2009 Feb; 284(7):4132-9. PubMed ID: 19060337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ATR-CHK1 pathway as a therapeutic target for acute and chronic leukemias.
    Boudny M; Trbusek M
    Cancer Treat Rev; 2020 Aug; 88():102026. PubMed ID: 32592909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer.
    Alsubhi N; Middleton F; Abdel-Fatah TM; Stephens P; Doherty R; Arora A; Moseley PM; Chan SY; Aleskandarany MA; Green AR; Rakha EA; Ellis IO; Martin SG; Curtin NJ; Madhusudan S
    Mol Oncol; 2016 Feb; 10(2):213-23. PubMed ID: 26459098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
    Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
    Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential roles of ATR and ATM in p53, Chk1, and histone H2AX phosphorylation in response to hyperoxia: ATR-dependent ATM activation.
    Kulkarni A; Das KC
    Am J Physiol Lung Cell Mol Physiol; 2008 May; 294(5):L998-L1006. PubMed ID: 18344416
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the ATR kinase enhances 5-FU sensitivity independently of nonhomologous end-joining and homologous recombination repair pathways.
    Ito SS; Nakagawa Y; Matsubayashi M; Sakaguchi YM; Kobashigawa S; Matsui TK; Nanaura H; Nakanishi M; Kitayoshi F; Kikuchi S; Kajihara A; Tamaki S; Sugie K; Kashino G; Takahashi A; Hasegawa M; Mori E; Kirita T
    J Biol Chem; 2020 Sep; 295(37):12946-12961. PubMed ID: 32675286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade.
    Ngoi NYL; Peng G; Yap TA
    Annu Rev Med; 2022 Jan; 73():231-250. PubMed ID: 34644155
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-338-3p confers 5-fluorouracil resistance in p53 mutant colon cancer cells by targeting the mammalian target of rapamycin.
    Han J; Li J; Tang K; Zhang H; Guo B; Hou N; Huang C
    Exp Cell Res; 2017 Nov; 360(2):328-336. PubMed ID: 28928082
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells.
    Harata S; Suzuki T; Takahashi H; Hirokawa T; Kato A; Watanabe K; Yanagita T; Ushigome H; Shiga K; Ogawa R; Mitsui A; Kimura M; Matsuo Y; Takiguchi S
    Oncol Rep; 2023 Mar; 49(3):. PubMed ID: 36734271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.